{"id":"mhb088c-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MHB088C binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing engagement with PD-1 and B7-1 receptors on T cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.","oneSentence":"MHB088C is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:17.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07126665","phase":"PHASE1, PHASE2","title":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","startDate":"2025-09-18","conditions":"Advanced Malignant Solid Tumor","enrollment":116},{"nctId":"NCT07102004","phase":"PHASE1, PHASE2","title":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-06-20","conditions":"Advanced/Metastatic Solid Tumors","enrollment":515},{"nctId":"NCT06954246","phase":"PHASE3","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-04","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":450},{"nctId":"NCT06951243","phase":"PHASE2","title":"A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-05-06","conditions":"Advanced Extrapulmonary Neuroendocrine Cancer","enrollment":40},{"nctId":"NCT05652855","phase":"PHASE1, PHASE2","title":"Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Minghui Pharmaceutical Pty Ltd","startDate":"2023-01-23","conditions":"Advanced or Metastatic Solid Tumors","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4550,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MHB088C for Injection","genericName":"MHB088C for Injection","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MHB088C is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}